标签归档：mmad

MMAD-d8(Synonyms: Demethyldolastatin 10-d8; Monomethylauristatin D-d8; Monomethyl Dolastatin 10-d8)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MMAD-d8 (Synonyms: Demethyldolastatin 10-d8; Monomethylauristatin D-d8; Monomethyl Dolastatin 10-d8) 纯度: 99.12%

D8-MMAD是MMAD的氘代形式。

MMAD-d8(Synonyms: Demethyldolastatin 10-d8; Monomethylauristatin D-d8; Monomethyl Dolastatin 10-d8)

MMAD-d8 Chemical Structure

规格 价格 是否有货 数量
1 mg ￥11000 In-stock
5 mg ￥25000 In-stock
10 mg ￥47000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

D8-MMAD is a deuterated form of MMAD, which is a microtubule disrupting agent.

IC50 & Target

Auristatin

 

体外研究
(In Vitro)

MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

779.11

Formula

C41H58D8N6O6S
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (128.35 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2835 mL 6.4176 mL 12.8352 mL
5 mM 0.2567 mL 1.2835 mL 2.5670 mL
10 mM 0.1284 mL 0.6418 mL 1.2835 mL

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。
参考文献

  • [1]. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

MMAD(Synonyms: Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MMAD (Synonyms: Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10) 纯度: 99.86%

MMAD 是一种有效的微管 (tubulin) 抑制剂，是抗体药物偶联物 (ADCs) 中的活性分子。

MMAD(Synonyms: Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10)

MMAD Chemical Structure

CAS No. : 203849-91-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
5 mg ￥800 In-stock
10 mg ￥1400 In-stock
50 mg ￥4500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

MMAD 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Toxins for Antibody-Drug Conjugate Research Library
  • Peptidomimetic Library

生物活性

MMAD is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugates (ADCs).

IC50 & Target

Auristatin

 

体外研究
(In Vitro)

MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

771.06

Formula

C41H66N6O6S
CAS 号

203849-91-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, stored under nitrogen

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。
溶解性数据
In Vitro: 

DMSO : 24.5 mg/mL (31.77 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2969 mL 6.4846 mL 12.9692 mL
5 mM 0.2594 mL 1.2969 mL 2.5938 mL
10 mM 0.1297 mL 0.6485 mL 1.2969 mL

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。
参考文献

  • [1]. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mc-MMAD

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mc-MMAD  纯度: 98.50%

Mc-MMAD 由高效微管抑制剂 MMAD 与保护基团 maleimidocaproyl 偶联而成。Mc-MMAD 可用于偶联抗体。

Mc-MMAD

Mc-MMAD Chemical Structure

CAS No. : 1401963-15-2

规格 价格 是否有货 数量
1 mg ￥5115 In-stock
5 mg ￥8649 In-stock
10 mg ￥13252 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC.

IC50 & Target

Auristatin

 

分子量

964.26

Formula

C51H77N7O9S
CAS 号

1401963-15-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (103.71 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0371 mL 5.1853 mL 10.3706 mL
5 mM 0.2074 mL 1.0371 mL 2.0741 mL
10 mM 0.1037 mL 0.5185 mL 1.0371 mL

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.59 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.59 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.59 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.59 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Antibody-drug conjugates Patent: WO 2013068874 A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Vc-MMAD

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Vc-MMAD  纯度: 98.82%

Vc-MMAD 由 linker (Val-Cit) 和微管抑制剂 MMAD 组成。Vc-MMAD 可用于偶联抗体。

Vc-MMAD

Vc-MMAD Chemical Structure

CAS No. : 1401963-17-4

规格 价格 是否有货 数量
1 mg ￥5000 In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

生物活性

Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a drug-linker conjugate for ADC.

IC50 & Target

Auristatin

 

分子量

1369.71

Formula

C70H104N12O14S
CAS 号

1401963-17-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Antibody-drug conjugates Patent: WO 2013068874 A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务